immunity News and Research

RSS

Mucosal delivery of IFNs a good strategy for COVID-19 prophylaxis post-exposure

Researchers from the UK and Germany recently reported a comprehensive characterization of the SARS-CoV-2 response of human nasal epithelial cells, revealing a response dominated by IFN-I/IIIs. Also, recombinant IFN-I/III treatment was found to efficiently block the replication of SARS-CoV-2, which suggests that mucosal delivery of IFNs may be a good strategy for prophylaxis post-exposure.

22 Feb 2021

SARS-CoV-2 DNA vaccine tested in animal model

A team of experts has tested the immune responses elicited by mucosal homologous plasmid and a heterologous immunization strategy using a plasmid vaccine and a Modified Vaccinia Ankara (MVA) expressing SARS-CoV-2 spike (S) and nucleocapsid (N) antigens.

21 Feb 2021

Novel SARS-CoV-2 vaccine utilizes recombinant spike protein with PIKA adjuvant

The primary aim of any vaccine is to stimulate immune functions and confer long-lasting protection. A paper recently uploaded to the preprint server bioRxiv by Tong et al. (17th Feb 2021) describes a novel vaccine utilizing PIKA adjuvant and recombinant spike proteins against COVID-19 disease that promises the generation of potent neutralization antibodies, which potentially support immune responses for years.

21 Feb 2021

Vaccination programs combined with physical distancing could contain COVID-19 resurgence

A combination of robust vaccination programs and strict physical distancing rules could avoid recurring peaks of COVID-19 without the need to rely on stay-at-home restrictions, according to a new study by epidemiologists and demographers from WorldPop at the University of Southampton, in collaboration with The Chinese University of Hong Kong.

20 Feb 2021

Interval between doses of Oxford COVID-19 vaccine can be safely extended to 3 months, suggests study

A 3-month interval between doses of the Oxford COVID-19 vaccine results in higher vaccine efficacy than a 6-week interval, with the first dose offering 76% protection in the 3 months between doses.

20 Feb 2021

Intranasal COVID-19 vaccine candidate preclinically tested at UAB expected to start clinical trial

The Altimmune Inc. vaccine candidate that was tested preclinically at the University of Alabama at Birmingham last year is expected to start patient enrollment for its Phase 1 clinical trial next week.

20 Feb 2021

Transforming immune killer T-cells into 'super soldiers' to fight against cancer

Creating "super soldiers" of specific white blood cells to boost an anti-tumour response has been shown in a series of elegant experiments by Princess Margaret researchers.

20 Feb 2021

Companies pan for marketing gold in vaccines

For a decade, Jennifer Crow has taken care of her elderly parents, who have multiple sclerosis. After her father had a stroke in December, the family got serious in its conversations with a retirement community — and learned that one service it offered was covid-19 vaccination.

19 Feb 2021

Live attenuated SARS-CoV-2 vaccine candidate shows protective efficacy in vivo

A new preprint on the bioRxiv* server describes the development of a live attenuated vaccine candidate to counter the growing threat of the COVID-19 pandemic.

19 Feb 2021

Chicken-derived antibody shows potent neutralizing capacity against SARS-CoV-2 in vitro

Researchers report on a Chicken-derived antibody against SARS-CoV-2, offering preliminary data on a potential therapeutic for COVID-19 warranting further research.

19 Feb 2021

Researchers use zebrafish to study cancer-immune interactions

Cancer researcher Rita Fior uses zebrafish to study human cancer. Though this may seem like an unlikely match, her work shows great promise with forthcoming applications in personalized medicine.

19 Feb 2021

Juvenile inflammatory rheumatic disease associated with higher antibody responses to seasonal coronaviruses

A new study released on the bioRxiv* server compared the antibodies produced in young patients with these three conditions against the two immunodominant coronavirus antigens, the spike and the nucleocapsid antigens.

19 Feb 2021

How does the SARS-CoV-2 E484K mutation increase viral fitness?

How do mutations benefit SARS-CoV-2? To explore this, a team of researchers from China took a closer look at the physical interactions that occur between the proteins after viral mutation.

19 Feb 2021

Study: First influenza infection does not make people immune to future flu viruses

A child's first influenza infection shapes their immunity to future airborne flu viruses - including emerging pandemic strains.

19 Feb 2021

Cologne University professor heads new consortium on EU vaccine research network

The European Union is funding the establishment of the new vaccine research network VACCELERATE with a total of 12 million euros for three years.

18 Feb 2021

Immune response to SARS-CoV-2 may be limited by a set of genes

Neutralizing antibodies develop within two weeks of a SARS-CoV-2 infection, but their durability and intensity can vary by individual, prompting concerns about the prospects of long-lasting immunity and efficacy of COVID-19 vaccines.

18 Feb 2021

Could measles virus vectors be used for a new COVID-19 vaccine?

A research team at the Institut Pasteur in France describes the successful development of such a vaccine utilizing a measles virus vector.

18 Feb 2021

Are antibody cocktails the key to COVID-19 treatment?

News-Medical speaks to Dr. Natalia Freund about her latest research into COVID-19, and how most people are capable of producing neutralizing antibodies against the virus.

18 Feb 2021

Tuberculosis vaccine could protect newborns against common infections

The tuberculosis (TB) vaccine Bacillus Calmette-Guerin (BCG) could protect newborns against a variety of common infections, such as upper respiratory tract infections, chest infections and diarrhoea, according to a new study in The Lancet Infectious Diseases.

18 Feb 2021

GDP significantly associated with greater COVID-19 vaccine distribution

ccording to a report published by the Bureau of Economic Analysis, the world's gross domestic product (GDP) fell by 4.6% in 2020. As per WHO estimates, at least 65% of the world population should be vaccinated to contain the virus's spread and achieve herd immunity.

17 Feb 2021

immunity News and Research

Mucosal delivery of IFNs a good strategy for COVID-19 prophylaxis post-exposure

SARS-CoV-2 DNA vaccine tested in animal model

Novel SARS-CoV-2 vaccine utilizes recombinant spike protein with PIKA adjuvant

Vaccination programs combined with physical distancing could contain COVID-19 resurgence

Interval between doses of Oxford COVID-19 vaccine can be safely extended to 3 months, suggests study

Intranasal COVID-19 vaccine candidate preclinically tested at UAB expected to start clinical trial

Transforming immune killer T-cells into 'super soldiers' to fight against cancer

Companies pan for marketing gold in vaccines

Live attenuated SARS-CoV-2 vaccine candidate shows protective efficacy in vivo

Chicken-derived antibody shows potent neutralizing capacity against SARS-CoV-2 in vitro

Researchers use zebrafish to study cancer-immune interactions

Juvenile inflammatory rheumatic disease associated with higher antibody responses to seasonal coronaviruses

How does the SARS-CoV-2 E484K mutation increase viral fitness?

Study: First influenza infection does not make people immune to future flu viruses

Cologne University professor heads new consortium on EU vaccine research network

Immune response to SARS-CoV-2 may be limited by a set of genes

Could measles virus vectors be used for a new COVID-19 vaccine?

Are antibody cocktails the key to COVID-19 treatment?

Tuberculosis vaccine could protect newborns against common infections

GDP significantly associated with greater COVID-19 vaccine distribution

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News